[go: up one dir, main page]

AR102246A1 - Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos - Google Patents

Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos

Info

Publication number
AR102246A1
AR102246A1 ARP150103294A ARP150103294A AR102246A1 AR 102246 A1 AR102246 A1 AR 102246A1 AR P150103294 A ARP150103294 A AR P150103294A AR P150103294 A ARP150103294 A AR P150103294A AR 102246 A1 AR102246 A1 AR 102246A1
Authority
AR
Argentina
Prior art keywords
osteoporosis
prevention
treatment
pharmaceutical compositions
aromatic compounds
Prior art date
Application number
ARP150103294A
Other languages
English (en)
Inventor
Grouix Brigitte
Gagnon Lyne
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of AR102246A1 publication Critical patent/AR102246A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32Phenylacetic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método para la prevención y/o el tratamiento de la osteoporosis, que comprende la etapa de administrarle a un sujeto que lo necesita un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable de este, en donde A es alquilo C₅, alquilo C₆, alquenilo C₅, alquenilo C₆, C(O)-(CH₂)ₙ-CH₃ o CH(OH)-(CH₂)ₙ-CH₃ en donde n es 3 ó 4; R¹ es H, F u OH; R² es H, F, OH, alquilo C₅, alquilo C₆, alquenilo C₅ alquenilo C₆, C(O)-(CH₂)ₙ-CH₃ o CH(OH)-(CH₂)ₙ-CH₃ en donde n es 3 ó 4; R³ es H, F, OH o CH₂Ph; R⁴ es H, F u OH; Q es 1) (CH₂)ₘC(O)OH en donde m es 1 ó 2, 2) CH(F)-C(O)OH, 3) CF₂-C(O)OH, o 4) C(O)-C(O)OH. Reivindicación 8: El método de cualquiera de las reivindicaciones de 1 a 7 caracterizado por que dicho compuesto se selecciona del grupo que consiste en los compuestos representados por las estructuras del grupo de fórmulas (2); y sales farmacéuticamente aceptables de estos.
ARP150103294A 2014-10-10 2015-10-13 Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos AR102246A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462062597P 2014-10-10 2014-10-10

Publications (1)

Publication Number Publication Date
AR102246A1 true AR102246A1 (es) 2017-02-15

Family

ID=55652429

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103294A AR102246A1 (es) 2014-10-10 2015-10-13 Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos

Country Status (23)

Country Link
US (2) US20180228750A1 (es)
EP (1) EP3203999B1 (es)
JP (1) JP6700639B2 (es)
KR (1) KR20170066476A (es)
CN (1) CN106999456B (es)
AR (1) AR102246A1 (es)
AU (1) AU2015330645B2 (es)
BR (1) BR112017007426A2 (es)
CA (1) CA2963354A1 (es)
DK (1) DK3203999T3 (es)
ES (1) ES2785317T3 (es)
IL (1) IL251404B (es)
MX (1) MX376873B (es)
MY (1) MY194308A (es)
PH (1) PH12017500638A1 (es)
PL (1) PL3203999T3 (es)
PT (1) PT3203999T (es)
RU (1) RU2709205C2 (es)
SG (1) SG11201702868VA (es)
TW (1) TWI699200B (es)
UY (1) UY36356A (es)
WO (1) WO2016054728A1 (es)
ZA (1) ZA201702639B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204000B1 (en) * 2014-10-10 2020-01-08 Liminal Biosciences Limited Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
RU2728782C2 (ru) * 2014-11-12 2020-07-31 Лиминал Байосайенсиз Лимитед Замещенные ароматические соединения и фармацевтические композиции для ауторепарации и регенерации ткани
KR20180006881A (ko) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
WO2018035449A1 (en) * 2016-08-18 2018-02-22 Intekrin Therapeutics, Inc. Pparϒ agonist for treatment of bone disorders
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
CN116568291A (zh) * 2020-10-06 2023-08-08 殷格纽制药有限公司 取代的芳香族化合物及其药物组合物
CA3237127A1 (en) * 2021-11-17 2023-05-25 Sanyasi R. Kalidindi Withania somnifera and asparagus racemosus in treating post-menopausal conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124662A1 (en) * 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
ES2441800T3 (es) * 2009-05-04 2014-02-06 Prometic Biosciences Inc. Sales de ácido 3-pentilfenilacético y usos farmacéuticos de las mismas
DK2427416T3 (en) * 2009-05-04 2016-06-13 Prometic Pharma Smt Ltd Substituted aromatic compounds, and pharmaceutical uses thereof
AU2011320057B2 (en) * 2010-10-27 2016-02-25 Liminal Biosciences Limited Phenylketone carboxylate compounds and pharmaceutical uses thereof
PH12013500766B1 (en) * 2010-10-27 2017-09-29 Prometic Pharma Smt Ltd Compounds and compositions for the treatment of cancer
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
EP3204000B1 (en) * 2014-10-10 2020-01-08 Liminal Biosciences Limited Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Also Published As

Publication number Publication date
AU2015330645A1 (en) 2017-05-04
PT3203999T (pt) 2020-04-23
JP2017530180A (ja) 2017-10-12
EP3203999B1 (en) 2020-01-08
ZA201702639B (en) 2018-06-27
MX376873B (es) 2025-03-07
CN106999456A (zh) 2017-08-01
PL3203999T3 (pl) 2020-07-27
US11185521B2 (en) 2021-11-30
BR112017007426A2 (pt) 2018-01-16
JP6700639B2 (ja) 2020-05-27
MY194308A (en) 2022-11-27
WO2016054728A1 (en) 2016-04-14
CA2963354A1 (en) 2016-04-14
US20180228750A1 (en) 2018-08-16
ES2785317T3 (es) 2020-10-06
US20200237693A1 (en) 2020-07-30
DK3203999T3 (da) 2020-03-30
EP3203999A1 (en) 2017-08-16
UY36356A (es) 2016-06-01
IL251404A0 (en) 2017-05-29
SG11201702868VA (en) 2017-05-30
AU2015330645B2 (en) 2020-03-12
IL251404B (en) 2020-11-30
PH12017500638A1 (en) 2017-09-25
CN106999456B (zh) 2020-07-10
RU2017116178A (ru) 2018-11-19
EP3203999A4 (en) 2018-06-27
TWI699200B (zh) 2020-07-21
KR20170066476A (ko) 2017-06-14
TW201618762A (zh) 2016-06-01
MX2017004733A (es) 2017-07-17
RU2709205C2 (ru) 2019-12-17
RU2017116178A3 (es) 2019-05-16

Similar Documents

Publication Publication Date Title
AR102246A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
UY36121A (es) ?pirazolopiridinas y pirazolopirimidinas?.
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
AR093759A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
AR100244A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR094550A1 (es) Inhibidores de btk
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
AR100694A1 (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cáncer
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR099874A1 (es) CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA
AR101696A1 (es) Compuestos de azetidiniloxifenilpirrolidina
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
EA201691675A1 (ru) Изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
UY36123A (es) Derivados de carboxamida
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ

Legal Events

Date Code Title Description
FB Suspension of granting procedure